2 options
Generic drug entry prior to patent expiration : an FTC study / Federal Trade Commission.
- Format:
- Book
- Government document
- Author/Creator:
- United States. Federal Trade Commission
- Language:
- English
- Subjects (All):
- Generic drugs--United States.
- Generic drugs.
- Drugs--United States--Patents.
- Drugs.
- Pharmacy--Law and legislation.
- Pharmacy.
- Drugs, Generic--economics.
- Legislation, Pharmacy.
- Patents as Topic--legislation & jurisprudence.
- United States.
- Medical Subjects:
- Drugs, Generic--economics.
- Legislation, Pharmacy.
- Patents as Topic--legislation & jurisprudence.
- United States.
- Genre:
- patents.
- Patents
- Patents.
- Physical Description:
- 1 online resource
- Place of Publication:
- [Washington, D.C.] : Federal Trade Commission, [2002]
- Summary:
- In April 2001, the Commission began an industry-wide study focused on certain aspects of generic drug competition under the Hatch-Waxman Amendments. The Amendments provide certain methods by which generic drug manufacturers can obtain approval to market a generic version of a brand-name product. The study's purpose was to provide a more complete picture of how generic drug competition has developed under one method the Amendments established: generic entry prior to expiration of the brand-name company's patents on the relevant drug product.
- Notes:
- Title from PDF title page (viewed September 20, 2005).
- "July 2002."
- OCLC:
- 50438405
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.